Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 1
2002 1
2003 1
2005 5
2006 6
2007 5
2008 7
2009 9
2010 5
2011 7
2012 4
2013 2
2014 3
2015 4
2016 1
2018 1
2019 2
2020 1
2021 3
2022 1
2023 9
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.
Dawed AY, Mari A, Brown A, McDonald TJ, Li L, Wang S, Hong MG, Sharma S, Robertson NR, Mahajan A, Wang X, Walker M, Gough S, Hart LM', Zhou K, Forgie I, Ruetten H, Pavo I, Bhatnagar P, Jones AG, Pearson ER; DIRECT consortium. Dawed AY, et al. Lancet Diabetes Endocrinol. 2023 Jan;11(1):33-41. doi: 10.1016/S2213-8587(22)00340-0. Lancet Diabetes Endocrinol. 2023. PMID: 36528349 Free article.
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.
Jungnik A, Arrubla Martinez J, Plum-Mörschel L, Kapitza C, Lamers D, Thamer C, Schölch C, Desch M, Hennige AM. Jungnik A, et al. Among authors: hennige am. Diabetes Obes Metab. 2023 Apr;25(4):1011-1023. doi: 10.1111/dom.14948. Epub 2023 Jan 30. Diabetes Obes Metab. 2023. PMID: 36527386 Clinical Trial.
Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Blüher M, et al. Among authors: hennige am. Diabetologia. 2024 Mar;67(3):470-482. doi: 10.1007/s00125-023-06053-9. Epub 2023 Dec 14. Diabetologia. 2024. PMID: 38095657 Free PMC article. Clinical Trial.
Perspectives in weight control in diabetes - Survodutide.
Klein T, Augustin R, Hennige AM. Klein T, et al. Among authors: hennige am. Diabetes Res Clin Pract. 2024 Jan;207:110779. doi: 10.1016/j.diabres.2023.110779. Epub 2023 Jun 15. Diabetes Res Clin Pract. 2024. PMID: 37330144
Genetic analysis of blood molecular phenotypes reveals common properties in the regulatory networks affecting complex traits.
Brown AA, Fernandez-Tajes JJ, Hong MG, Brorsson CA, Koivula RW, Davtian D, Dupuis T, Sartori A, Michalettou TD, Forgie IM, Adam J, Allin KH, Caiazzo R, Cederberg H, De Masi F, Elders PJM, Giordano GN, Haid M, Hansen T, Hansen TH, Hattersley AT, Heggie AJ, Howald C, Jones AG, Kokkola T, Laakso M, Mahajan A, Mari A, McDonald TJ, McEvoy D, Mourby M, Musholt PB, Nilsson B, Pattou F, Penet D, Raverdy V, Ridderstråle M, Romano L, Rutters F, Sharma S, Teare H, 't Hart L, Tsirigos KD, Vangipurapu J, Vestergaard H, Brunak S, Franks PW, Frost G, Grallert H, Jablonka B, McCarthy MI, Pavo I, Pedersen O, Ruetten H, Walker M; DIRECT Consortium; Adamski J, Schwenk JM, Pearson ER, Dermitzakis ET, Viñuela A. Brown AA, et al. Nat Commun. 2023 Aug 21;14(1):5062. doi: 10.1038/s41467-023-40569-3. Nat Commun. 2023. PMID: 37604891 Free PMC article.
Stratification of obesity phenotypes to optimize future therapy (SOPHIA).
Tahrani AA, Panova-Noeva M, Schloot NC, Hennige AM, Soderberg J, Nadglowski J, Tarasenko L, Ahmad NN, Sleypen BS, Bravo R, Al-Najim W, le Roux CW. Tahrani AA, et al. Among authors: hennige am. Expert Rev Gastroenterol Hepatol. 2023 Jul-Dec;17(10):1031-1039. doi: 10.1080/17474124.2023.2264783. Epub 2023 Oct 24. Expert Rev Gastroenterol Hepatol. 2023. PMID: 37791820 Review.
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity.
Yazawa R, Ishida M, Balavarca Y, Hennige AM. Yazawa R, et al. Among authors: hennige am. Diabetes Obes Metab. 2023 Jul;25(7):1973-1984. doi: 10.1111/dom.15064. Epub 2023 Apr 27. Diabetes Obes Metab. 2023. PMID: 36974349 Clinical Trial.
Correction to: Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.
Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM. Blüher M, et al. Among authors: hennige am. Diabetologia. 2024 Apr;67(4):758. doi: 10.1007/s00125-024-06095-7. Diabetologia. 2024. PMID: 38349400 Free PMC article. No abstract available.
76 results